<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35857139</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Motor-neuron-disease-like phenotype associated with IgLON5 disease.</ArticleTitle><Pagination><StartPage>6139</StartPage><EndPage>6144</EndPage><MedlinePgn>6139-6144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11262-0</ELocationID><Abstract><AbstractText>A growing spectrum of neurological manifestations are being recognized in association with IgLON5 autoimmunity, including recent reports of motor-neuron-disease-like phenotype. Here we describe four cases of IgLON5 autoimmunity with motor neuron involvement and evaluate an additional 109 probable or definite amyotrophic lateral sclerosis cases seen in our neuromuscular clinic for IgLON5-IgG seropositivity. The presence of parasomnias, vocal cord dysfunction or hyperkinetic movements in a patient with motor-neuron-disease-like phenotype should prompt evaluation for IgLON5-IgG autoantibodies. Recognition and treatment of this autoimmune disease with immunosuppressive agents may bring about significant neurological improvement in a minority of cases.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sista</LastName><ForeName>Sri Raghav</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crum</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aboseif</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devine</LastName><ForeName>Michelle F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zekeridou</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammami</LastName><ForeName>M Bakri</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezk</LastName><ForeName>Mohammed M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truffert</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Neurosciences, Faculty of Medicine, University Hospital of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalive</LastName><ForeName>Patrice H</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Neurosciences, Faculty of Medicine, University Hospital of Geneva, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunchok</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeon</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubey</LastName><ForeName>Divyanshu</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6865-9045</Identifier><AffiliationInfo><Affiliation>Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN, 55905, USA. Dubey.divyanshu@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Dubey.divyanshu@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA. Dubey.divyanshu@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS126227</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000591569">IgLON5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">IgLON5 autoimmunity</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword></KeywordList><CoiStatement><b>Conflicts of interest</b> The authors declare that they have no conflict of interest related to the work submitted for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>20</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35857139</ArticleId><ArticleId IdType="mid">NIHMS1840325</ArticleId><ArticleId IdType="pmc">PMC9578379</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11262-0</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11262-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Landa J et al. (2020) Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. Ann Neurol 88(5):1023&#x2013;1027</Citation><ArticleIdList><ArticleId IdType="pubmed">32740999</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabater L et al. (2014) A novel non-rapid-eye movement and rapideye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13(6):575&#x2013;586</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4104022</ArticleId><ArticleId IdType="pubmed">24703753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaig C, Compta Y (2019) Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Curr Opin Neurol 32(3):493&#x2013;499</Citation><ArticleIdList><ArticleId IdType="pubmed">30694925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenninger S (2017) Expanding the clinical spectrum of IgLON5-syndrome. J Neuromuscul Dis 4(4):337&#x2013;339</Citation><ArticleIdList><ArticleId IdType="pubmed">29103046</ArticleId></ArticleIdList></Reference><Reference><Citation>Honorat JA et al. (2017) IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol-Neuroimmunol Neuroinflamm 4(5):e385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5515599</ArticleId><ArticleId IdType="pubmed">28761904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao QQ et al. (2018) Motor neuron disease-like phenotype associated with anti-IgLON5 disease. CNS Neurosci Ther 24(12):1305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490080</ArticleId><ArticleId IdType="pubmed">30105827</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner J et al. (2021) Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurology-Neuroimmunol Neuroinflamm 8(2):e692</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057065</ArticleId><ArticleId IdType="pubmed">33531378</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E et al. (2016) Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 132(4):531&#x2013;543</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023728</ArticleId><ArticleId IdType="pubmed">27358064</ArticleId></ArticleIdList></Reference><Reference><Citation>Videnovic A et al. (2022) Case 1&#x2013;2022: a 67-year-old man with motor neuron disease and odd behaviors during sleep. N Engl J Med 386(2):173&#x2013;180</Citation><ArticleIdList><ArticleId IdType="pubmed">35020988</ArticleId></ArticleIdList></Reference><Reference><Citation>Graus F, Santamaria J (2017) Understanding anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm 4(5):e393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570673</ArticleId><ArticleId IdType="pubmed">28852690</ArticleId></ArticleIdList></Reference><Reference><Citation>Erro ME et al. (2020) Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy. Neurol-Neuroimmunol Neuroinflamm 7(2):e651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007636</ArticleId><ArticleId IdType="pubmed">31826985</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>